9 recruiting, 9 unknown, 4 not yet recruiting, 2 completed. 22 Phase 2, 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Recruiting 9, Unknown 6, Not yet recruiting 4, Completed 2, Active not recruiting 1 |
| Phase 1 | 3 | Unknown 2, Not yet recruiting 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow Tislelizumab: new trials by email Literature Review of Tislelizumab trials Research Report on Tislelizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC Tislelizumab, Intravenous Chemotherapy, Bronchial Artery Chemoembolization (BACE) - Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab | Phase 2 | Not yet recruiting | Sichuan Cancer Hospital and Research Institute | 39 | 2026-05-01 | 2026-05-01 |
| Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 Tislelizumab, Becotatug Vedotin, Cisplatin - ESCC, Tislelizumab | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 93 | 2026-04-01 | 2026-04-15 |
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer CRT+PD-1 inhibitor+Probio-M9, CRT+PD-1 inhibitor+placebo - Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Seventh Medical Center of PLA General Hospital | 50 | 2026-02-10 | 2026-03-10 |
| Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 inhibitors, Chemotherapy - Borderline Resectable Carcinoma, Unresectable Cancer | Phase 2 | Recruiting | Chuangzhen Chen | 39 | 2025-12-05 | 2026-10-05 |
| Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer Nab-paclitaxel, Tislelizumab, endoscopic intervention - Renal Pelvic Carcinoma, Tislelizumab | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-11-25 | 2025-11-18 |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study neoadjuvant therapy, Surgery, Adjuvant therapy - NSCLC, Tislelizumab | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 34 | 2025-07-25 | 2026-10-13 |
| Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer Surufatinib, Tislelizumab, Concurrent Chemotherapy - Surufatinib, Tislelizumab | Phase 2 | Recruiting | Sun Yat-sen University | 80 | 2025-07-20 | 2025-07-25 |
| Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer PD-1 inhibitior, Nab-paclitaxel, distal ureterectomy - Ureteral Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-15 |
| Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer fruquintinib + tislelizumab + FOLFOX - Gastric (Stomach) Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 44 | 2025-03-01 | 2025-03-12 |
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Tislelizumab - Hepatocellular Carcinoma, Radiotherapy | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-01-25 | 2026-04-17 |
| Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study SBRT combined with Tislelizumab followed by Tislelizumab - NSCLC, Tislelizumab | Phase 2 | Recruiting | Zibo Municipal Hospital | 20 | 2024-01-13 | 2025-07-25 |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer HAIC, Surufatinib, Tislelizumab - Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 41 | 2023-11-01 | 2023-11-18 |
| XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine - Tislelizumab, Bevacizumab | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 52 | 2023-07-07 | 2023-08-01 |
| Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors TACE, Tislelizumab, Lenvatinib - Hepatocellular Carcinoma, Lenvatinib | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 35 | 2023-07-01 | 2025-02-11 |
| Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer Tislelizumab - MSI-H Colorectal Cancer, Tislelizumab | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 25 | 2023-06-01 | 2023-05-09 |
| Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC Tislelizumab, Paclitaxel, Carboplatin - Esophageal Squamous Cell Carcinoma, Tislelizumab | Phase 1 / Phase 2 | Unknown | Jiangsu Cancer Institute & Hospital | 30 | 2022-05-01 | 2022-05-27 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary Tislelizumab plus chemotherapy - Cancer of Unknown Primary, Bone Cancer Metastatic | Phase 2 | Unknown | Wei Xu | 27 | 2021-11-12 | 2022-02-15 |
| Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma Tislelizumab in combination with anlotinib - Pulmonary Pleomorphic Carcinoma, Immunotherapy | Phase 2 | Completed | Second Affiliated Hospital of Nanchang University | 29 | 2021-08-17 | 2026-05-28 |
Showing 20 of 25. Sign in to see all of them.
Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Stomach Neoplasms (2) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Neoplasm, Residual (1) · Neoplasms (1) · Rectal Neoplasms (1) · Ureteral Neoplasms (1) · Uterine Cervical Neoplasms (1)
Neoplasms (13) · Neoplasms by Site (13) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Carcinoma (4) · Adenocarcinoma (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Rectal Diseases (3) · Carcinoma, Squamous Cell (2) · Colonic Diseases (2)
tislelizumab (17) · 130-nm albumin-bound paclitaxel (3) · Paclitaxel (3) · Radiotherapy (3) · Carboplatin (2) · Cisplatin (2) · Drug Therapy (2) · HMPL-013 (2) · Surgical Procedures, Operative (2) · lenvatinib (2) · surufatinib (2) · Capecitabine (1) · Chemotherapy, Adjuvant (1) · Folfox protocol (1) · Immune Checkpoint Inhibitors (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Tianjin Medical University Second Hospital (2) · Zibo Municipal Hospital (2) · Cancer Hospital of Guangxi Medical University (1) · Chuangzhen Chen (1) · Hao Long (1) · Jiangsu Cancer Institute & Hospital (1) · Lei Li (1) · M.D. Anderson Cancer Center (1) · Qilu Hospital of Shandong University (1) · Second Affiliated Hospital of Nanchang University (1) · Seventh Medical Center of PLA General Hospital (1) · Sichuan Cancer Hospital and Research Institute (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Sun Yat-sen University (1)
China (22) · United States (1)
Arvind Dasari, MD (1) · Bo Li, Profession (1) · Guohui Xu, MD (1) · Hailong Hu, PhD (1) · Hao Jiang, Doctor (1) · Jianru Xiao, Profession (1) · Lei Li, M.D. (1) · Lin Yang (1) · Pengru Wang, Doctor (1) · Wei Xu, Profession (1) · Xiangzhi Zhu, Dr. (1) · Xuegang Yang, MD (1)